Endo Health Solutions' quarterly profit of anesthetic and generic drugs beat analysts' expectations with a $785 million — or 29 percent — revenue increase, according to Reuters.
Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
First Grad Completes TeamHealth Anesthesia Management Fellowship
Colorado Court Says CRNAs Can Administer Anesthesia
Somnia Releases White Paper on Anesthesia's Role in Perioperative Management
Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
First Grad Completes TeamHealth Anesthesia Management Fellowship
Colorado Court Says CRNAs Can Administer Anesthesia
Somnia Releases White Paper on Anesthesia's Role in Perioperative Management